The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including ...

LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority ...

Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...

Mustang Bio has received orphan drug designation from the US Food and Drug Administration (FDA) for MB-108, a herpes simplex ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Sonnet BioTherapeutics has announced the issuance of US Patent No. 12,134,635 covering its two new drug candidates, SON-1411 ...

Advancing to first-in-human clinical trials requires formulation development to design a successful sterile formulation that ...

Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001to treat uveitic ...

In Canada pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.

In the global pharmaceutical industry, there were three private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.

In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.

In the global pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $7.5m, according to GlobalData's Deals Database.